Urologische Partnerschaft Köln UPK
- Address
- Bernhardstrasse 110, 50968 Cologne, Germany
Urologische Partnerschaft Köln UPK - Bladder Cancer Research Center
The Urologische Partnerschaft Köln UPK is a specialized urological research center dedicated to advancing treatment options for patients with bladder cancer. The center focuses on innovative therapeutic approaches for non-muscle invasive bladder cancer, particularly investigating novel drug delivery systems and targeted therapies for patients with specific genetic alterations.
- FGFR-positive intermediate-risk non-muscle invasive bladder cancer treatment optimization
- Intravesical drug delivery systems and novel instillation therapies
- Comparative effectiveness research in bladder-sparing oncological interventions
The center's research portfolio emphasizes targeted molecular therapies for bladder cancer patients with FGFR gene alterations, evaluating disease-free survival outcomes with innovative treatment modalities. Their work contributes to the development of precision medicine approaches in urological oncology, with particular attention to intermediate-risk patient populations who may benefit from bladder-preserving strategies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Janssen Cilag International1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Urologische Partnerschaft Köln UPK
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of TAR-200 and Cetrelimab Versus Bacillus Calmette-Guérin in BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer | Janssen Cilag International | Phase III | Not Recruiting | Mar 2023 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Gemcitabine Hydrochloride | 2 | Unknown | 2023-03-23 | 2024-07-24 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.